Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

M. Talpaz, P. Rousselot, D.W. Kim, F. Guilhot, S. Corm, E. Bleickardt, R. Zink, G. Rosti, S. Coutre, C. Sawyers

Blood (2005) 106 (11): 40.

https://doi.org/10.1182/blood.V106.11.40.40

Published: 2005

Journal Articles

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Charles L. Sawyers, H. Kantarjian, N. Shah, J. Cortes, R. Paquette, N. Donato, J. Nicoll, E. Bleickardt, T.-T. Chen, M. Talpaz

Blood (2005) 106 (11): 38.

https://doi.org/10.1182/blood.V106.11.38.38

Published: 2005

Journal Articles

Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

HM Kantarjian, S O'Brien, P Anderlini, M Talpaz

Blood (1996) 87 (8): 3069–3081.

https://doi.org/10.1182/blood.V87.8.3069.bloodjournal8783069

Published: 1996

Journal Articles

Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation

Z Estrov, RA Black, PR Sleath, D Harris, Q Van, R LaPushin, EH Estey, M Talpaz

Blood (1995) 86 (12): 4594–4602.

https://doi.org/10.1182/blood.V86.12.4594.bloodjournal86124594

Published: 1995

Journal Articles

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

S O'Brien, H Kantarjian, M Keating, M Beran, C Koller, LE Robertson, J Hester, MB Rios, M Andreeff, M Talpaz

Blood (1995) 86 (9): 3322–3326.

https://doi.org/10.1182/blood.V86.9.3322.bloodjournal8693322

Published: 1995

Journal Articles

Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment

DC Seong, HM Kantarjian, JY Ro, M Talpaz, J Xu, JR Robinson, AB Deisseroth, RE Champlin, MJ Siciliano

Blood (1995) 86 (6): 2343–2349.

https://doi.org/10.1182/blood.V86.6.2343.bloodjournal8662343

Published: 1995

Journal Articles

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

M Talpaz, H Kantarjian, J Liang, L Calvert, J Hamer, P Tibbits, A Durett, D Claxton, S Giralt, I Khouri

Blood (1995) 85 (11): 3257–3263.

https://doi.org/10.1182/blood.V85.11.3257.bloodjournal85113257

Published: 1995

Journal Articles

Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia

CF Verschraegen, M Talpaz, CF Hirsch-Ginsberg, R Pherwani, MB Rios, SA Stass, HM Kantarjian

Blood (1995) 85 (10): 2705–2710.

https://doi.org/10.1182/blood.V85.10.2705.bloodjournal85102705

Published: 1995

Journal Articles

Interferon-{alpha} Therapy in Chronic Myelogenous Leukemia: Questions Related to the German Randomized Trial

H. M. Kantarjian, M. Talpaz

Blood (1995) 85 (10): 2998–2999.

https://doi.org/10.1182/blood.V85.10.2998.bloodjournal85102998

Published: 1995

Journal Articles

Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis [see comments]

JE Cortes, M Talpaz, F Cabanillas, JF Seymour, R Kurzrock

Blood (1995) 85 (9): 2516–2520.

https://doi.org/10.1182/blood.V85.9.2516.bloodjournal8592516

Published: 1995

Journal Articles

Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates

M Wetzler, R Kurzrock, Z Estrov, H Kantarjian, H Gisslinger, MP Underbrink, M Talpaz

Blood (1994) 84 (9): 3142–3147.

https://doi.org/10.1182/blood.V84.9.3142.3142

Published: 1994

Journal Articles

BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy

JQ Guo, JY Lian, YM Xian, MS Lee, AB Deisseroth, SA Stass, RE Champlin, M Talpaz, JY Wang, RB Arlinghaus

Blood (1994) 83 (12): 3629–3637.

https://doi.org/10.1182/blood.V83.12.3629.3629

Published: 1994

Journal Articles

Chronic myelogenous leukemia: a concise update

HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz

Blood (1993) 82 (3): 691–703.

https://doi.org/10.1182/blood.V82.3.691.691

Published: 1993

Journal Articles

Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors

Z Estrov, R Kurzrock, E Estey, M Wetzler, A Ferrajoli, D Harris, M Blake, JU Gutterman, M Talpaz

Blood (1992) 79 (8): 1938–1945.

https://doi.org/10.1182/blood.V79.8.1938.1938

Published: 1992

Journal Articles

Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy

MS Lee, H Kantarjian, M Talpaz, EJ Freireich, A Deisseroth, JM Trujillo, SA Stass

Blood (1992) 79 (8): 1920–1923.

https://doi.org/10.1182/blood.V79.8.1920.1920

Published: 1992

Journal Articles

Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia

D Claxton, A Deisseroth, M Talpaz, C Reading, H Kantarjian, J Trujillo, S Stass, G Gooch, G Spitzer

Blood (1992) 79 (4): 997–1002.

https://doi.org/10.1182/blood.V79.4.997.997

Published: 1992

Journal Articles

Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression

M Wetzler, R Kurzrock, DG Lowe, H Kantarjian, JU Gutterman, M Talpaz

Blood (1991) 78 (9): 2400–2406.

https://doi.org/10.1182/blood.V78.9.2400.2400

Published: 1991

Journal Articles

Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia

HM Kantarjian, M Talpaz, K Dhingra, E Estey, MJ Keating, S Ku, J Trujillo, Y Huh, S Stass, R Kurzrock

Blood (1991) 78 (9): 2411–2418.

https://doi.org/10.1182/blood.V78.9.2411.2411

Published: 1991

Journal Articles

Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity

Z Estrov, R Kurzrock, M Wetzler, H Kantarjian, M Blake, D Harris, JU Gutterman, M Talpaz

Blood (1991) 78 (6): 1476–1484.

https://doi.org/10.1182/blood.V78.6.1476.1476

Published: 1991

Journal Articles

Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias

K Dhingra, M Talpaz, MG Riggs, PS Eastman, T Zipf, S Ku, R Kurzrock

Blood (1991) 77 (2): 238–242.

https://doi.org/10.1182/blood.V77.2.238.238

Published: 1991

NARROW

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia

Interferon-{alpha} Therapy in Chronic Myelogenous Leukemia: Questions Related to the German Randomized Trial

Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis [see comments]

Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates

BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy

Chronic myelogenous leukemia: a concise update

Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors

Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy

Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia

Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression

Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia

Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity

Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only